ArticleBreast cancer (Tokyo, Japan)2026
A dynamic nomogram predicting persistent breast cancer-related lymphedema: a retrospective cohort study in China.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinician Perspectives on Implementing Breast Cancer-Related Lymphedema Prospective Screening.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundOnce developed, persistent lymphedema (PLE) is irreversible and imposes multiple adverse challenges and a heavy economic burden on patients and the healthcare industry. This study aims to develop a risk nomogram model for PLE in breast cancer-related lymphedema (BCRL) patients and visualize it as a free online prediction website to guide individualized risk stratification and graded management.
methods418 BCRL patients who underwent axillary lymph node dissection (ALND) among 2176 postoperative breast cancer patients from January 2020 to December 2022 were retrospectively enrolled as research subjects. Univariate and logistic regression models were performed to identify risk factors. A visual dynamic nomogram was constructed using R and Shinyapps software, followed by validation of its discrimination, calibration, and clinical validity.
resultsPLE incidence was 32.78%. Age, ALND level, severity of lymphedema, dominant side, and lymph node metastasis were significant risk factors for PLE (P < 0.05). The nomogram's C index was 0.827 (95%CI 0.774-0.880) in the training cohort and 0.849 (95%CI 0.782-0.916) in the validation cohort. Calibration curves showed good consistency across both cohorts. Decision curve analysis confirmed the good clinical validity, identifying 36% as the optimal threshold probability.
conclusionThe dynamic nomogram, leveraging readily available clinical parameters, offers a clinically applicable web-based platform for dynamic risk quantification of PLE, facilitating early prediction, resource allocation, and prognosis management for high-risk PLE patients.
Indexed as
Identifiers
40983818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.